An Activated ErbB 3 / NRG 1 Autocrine Loop Supports In Vivo Proliferation in Ovarian Cancer Cells

Qing Sheng,1,3 Xinggang Liu,1,3 Eleanor Fleming,1,3 Karen Yuan,1,3 Huiying Piao,2,3,4 Jinyun Chen,6 Zeinab Moustafa,6 Roman K. Thomas,7,8,9 Heidi Greulich,2,3,5,10 Anna Schinzel,2,3,10 Sara Zaghlul,1,3 David Batt,6 Seth Ettenberg,6 Matthew Meyerson,2,3,10 Birgit Schoeberl,11 Andrew L. Kung,3,12 William C. Hahn,2,3,10 Ronny Drapkin,2,3,4 David M. Livingston,1,3,* and Joyce F. Liu1,2,3 1Department of Cancer Biology 2Department of Medical Oncology Dana-Farber Cancer Institute, Boston, MA 02115, USA 3Harvard Medical School, Boston, MA 02115, USA 4Department of Pathology 5Department of Medicine Brigham and Women’s Hospital, Boston, MA 02115, USA 6Novartis Oncology, Cambridge, MA 02139, USA 7Max Planck Institute for Neurological Research with Klaus-Joachim Zülch Laboratories, Max Planck Society and the Medical Faculty of the University of Köln, D-50931 Köln, Germany 8Department I of Internal Medicine and Center of Integrated Oncology, University of Köln, D-50937 Köln, Germany 9Chemical Genomics Center of the Max Planck Society, D-44227 Dortmund, Germany 10Broad Institute of Harvard University and the Massachusetts Institute of Technology, Cambridge, MA 02142, USA 11Merrimack Pharmaceuticals, Cambridge, MA 02139, USA 12Department of Pediatric Oncology, Dana-Farber Cancer Institute and Children’s Hospital, Boston, MA 02115, USA *Correspondence: david_livingston@dfci.harvard.edu DOI 10.1016/j.ccr.2009.12.047